Cellsway is a fresh deep-tech start-up founded in March 2020 in UK to convert the know-how and cutting-edge core technology that have been developed and cultivated at Mikro Biyosistemler Inc. into commercial products to set the gold standard for diagnosis and management of cancer. The flagship product of the company is a liquid biopsy platform which uses a simple blood sample for cancer diagnostics and cancer research. The patent-pending microfluidic technology enables isolation and enumeration of Circulating Tumor Cells (CTCs) from the blood samples of cancer patients.